Growing Personalized Medicine Capabilities, PGXL Inks Partnership with AutoGenomics

PGXL will use AutoGenomics' Infiniti analyzer for various personalized medicine applications. Specifically, PGXL plans to use AutoGenomics' FDA-cleared Infiniti warfarin assay and CYP450 2C19 assay.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.